尼罗替尼300 mg每日两次给药用于CML的一线治疗：针对Xpert BCR-ABL监控系统的前瞻性分析和三个月分子学缓解的意义

Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p = 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.

主要结论：尼罗替尼300 mg每日两次给药治疗可以获得较高的完全细胞遗传学缓解和主要分子学缓解比例。Xpert系统是评估TKI治疗效果有效、快速的方法。三个月时，与BCR-ABL1/ABL1IS与<1%相比，BCR-ABL1/ABL1IS>1%且<10%者的四个半月时的分子学缓解率较低。